⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 22, 2025

Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Rona Yaeger Riccardo Mezzadra Jenna Sinopoli Yu Bian Michelangelo Marasco Esther Kaplun Yijun Gao HuiYong Zhao Arnaud Da Cruz Paula Yingjie Zhu Almudena Chaves Perez Kalyani Chadalavada Edison Tse Sudhir Chowdhry Sydney Bowker Qing Chang Besnik Qeriqi Britta Weigelt Gouri J. Nanjangud Michael F. Berger Hirak Der‐Torossian Kenna Anderes Nicholas D. Socci Jinru Shia Gregory J. Riely Yonina R. Murciano‐Goroff Bob T. Li James G. Christensen Jorge S. Reis‐Filho David B. Solit Elisa de Stanchina Scott W. Lowe Neal Rosen Sandra Misale

View Full Paper

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Acquired resistance mechanisms to KRAS-G12C-EGFR inhibition are characterized in colorectal cancer cell lines.
KEY EVIDENCE: Single cell sequencing analysis provides detailed insights into resistance pathways.
APPROACH: C106 cell lines underwent rigorous molecular characterization through single cell sequencing.
SIGNIFICANCE: Understanding these resistance mechanisms could guide more effective therapies for colorectal cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals resistance mechanisms to KRAS-G12C-EGFR inhibition in colorectal cancer cell lines, highlighting cell sequencing insights.

Abstract

C106 cell lines single cell sequencing analysis

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yaeger et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd949 https://doi.org/10.1158/2159-8290.29619033

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
2Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
3Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
4Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer2025
5Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024